Litronesib Racemate

• CAT Number: I004007
• CAS Number: 546111-97-1
• Molecular Formula: C23H37N5O4S2
• Molecular Weight: 511.70
• Purity: ≥95%
• Target: Cytoskeleton
• Solubility: DMSO
• IUPAC Name: N-[4-(2,2-dimethylpropanoyl)-5-[[2-(ethylamino)ethylsulfonylamino]methyl]-5-phenyl-1,3,4-thiadiazol-2-yl]-2,2-dimethylpropanamide
• InChI: 1S/C23H37N5O4S2/c1-8-24-14-15-34(31,32)25-16-23(17-12-10-9-11-13-17)28(19(30)22(5,6)7)27-20(33-23)26-18(29)21(2,3)4/h9-13,24-25H,8,14-16H2,1-7H3,(H,26,27,29)
• InChIKey: YVAFBXLHPINSIK-UHFFFAOYSA-N
• SMILES: CCNCCS(=O)(=O)NCC1(N(N=C(S1)NC(=O)C(C)(C)C)C(=O)C(C)(C)C)C2=CC=CC=C2

Litronesib racemate (Cat No.: I004007) is a small-molecule inhibitor of Eg5 (kinesin spindle protein, KSP), an essential motor protein involved in mitotic spindle formation during cell division. By inhibiting Eg5, litronesib disrupts mitosis, leading to cell cycle arrest and apoptosis, particularly in rapidly dividing cancer cells. The racemate form contains both enantiomers of the compound, used in early-stage research to evaluate efficacy and pharmacokinetics. Litronesib racemate has been explored as an anticancer agent in preclinical and clinical studies, especially for solid tumors and hematologic malignancies.